<DOC>
	<DOCNO>NCT02727803</DOCNO>
	<brief_summary>The goal clinical research study learn give cell call natural killer ( NK ) cell receive 1 3 pre-treatment plan UCB transplant improve response patient MDS , leukemia , lymphoma , MM . The safety treatment whether NK cell lessen risk graft versus host disease ( GVHD ) also study . If disease CD20 positive , also receive rituximab study addition describe . CD20 type marker white blood cell . White blood cell help protect body infection . NK cell may kill cancer cell remain body last chemotherapy treatment . The NK cell separate umbilical cord blood . The device use laboratory separate NK cell call CliniMACS . These separate NK cell grown lab increase number NK cell give vein . Based gene , NK cell may recover quickly transplant . Before transplant , blood collect genetic test part standard screening test . If genetic test show NK cell recover quickly transplant , receive NK cell infusion .</brief_summary>
	<brief_title>Personalized Natural Killer ( NK ) Cell Therapy Cord Blood Transplantation ( CBT )</brief_title>
	<detailed_description>Study Drug Administration : The day receive UCB transplant call minus ( - ) day . The day receive UCB transplant call Day 0 . The day receive UCB transplant call plus ( + ) day . Before receive UCB transplant , receive 1 3 chemotherapy treatment choose doctor . The treatment select base age health . Each plan describe detail . Treatment Plan # 1 : If assign plan , receive busulfan , fludarabine , clofarabine , antithymocyte globulin ( ATG ) vein , well total body irradiation ( TBI ) , accord follow schedule . Before Day -10 , receive low-level `` test '' dose busulfan vein 45 minute 1 hour . Test dos use study body break busulfan decide dose busulfan receive . You may receive test dose Day -10 outpatient clinic , Day -9 inpatient hospital . Blood ( 1 teaspoon time ) drawn pharmacokinetic ( PK ) test 11 time 11 hour busulfan test dose . PK test measure amount busulfan body different time point . The study staff tell PK test schedule . A heparin lock line ( special kind IV heparin prevent clot ) place vein PK test help low number needle stick need draws . This allow study staff draw blood heparin lock line instead stick needle multiple time . If reason possible PK test perform , receive standard dose busulfan . On Day -10 , admit hospital give fluid vein hydrate . On Days -9 -8 , receive ATG vein 4 hour . ATG design weaken immune system order low risk body reject transplant . On Days -7 -4 , receive fludarabine vein 1 hour , clofarabine vein 1 hour , busulfan vein 3 hour . On Day -3 , receive TBI . TBI involve delivery high dos radiation design destroy cancer cell and/or low immune system order low risk body reject new stem cell . On Days -2 -1 , rest . On Day 0 , receive UCB transplant vein . This consist 2 CB unit infuse separately . Between Day +30 +80 , cord blood select transplant match genetic makeup , may receive NK cell vein . You give standard drug help decrease risk side effect . You may ask study staff information drug give risk . Treatment Plan # 2 : If assign plan , receive rituximab , fludarabine , cyclophosphamide , mesna , ATG vein , well total body irradiation ( TBI ) , accord follow schedule . On Day -10 , disease CD20 positive , admitted hospital give fluid vein hydrate , Day -9 , receive rituximab vein 6 hour . On Day -9 , disease CD20 positive , admitted hospital give fluid vein hydrate . You receive rituximab . On Days -8 -7 , receive ATG vein 4 hour . ATG design weaken immune system order low risk body reject transplant . On Day -6 , receive fludarabine vein 1 hour cyclophosphamide vein 3 hour . You also receive mesna vein cyclophosphamide help low risk side effect bladder . On Days -5 -3 , receive fludarabine vein 1 hour . On Day -2 , rest . On Day -1 , receive total body irradiation ( TBI ) . TBI involve delivery high dos radiation design destroy cancer cell and/or low immune system order low risk body reject new stem cell . On Day 0 , receive UCB transplant vein . This consist 2 CB unit infuse separately . Between Day +30 +80 , cord blood select transplant match genetic makeup , may receive NK cell vein . This consist 2 CB unit infuse separately . You give standard drug help decrease risk side effect . You may ask study staff information drug give risk . Treatment Plan # 3 : If assign plan , receive fludarabine , ATG , melphalan vein accord follow schedule . On Day -8 , admit hospital give fluid vein hydrate . On Days -7 -6 , receive ATG vein 4 hour . ATG design weaken immune system order low risk body reject transplant . On Days -5 -2 , receive fludarabine vein 1 hour . On Day -2 , receive melphalan vein 30 minute . On Day -1 , rest . On Day 0 , receive UCB transplant vein . This consist 2 CB unit infuse separately . Between Day +30 +80 , cord blood select transplant match genetic makeup , receive NK cell vein . You give standard drug help decrease risk side effect . You may ask study staff information drug give risk . Study Visits : You stay hospital 2-4 week UCB transplant . While hospital , check side effect may blood ( 2 teaspoon ) draw routine test daily Day +100 . Blood test may perform often , doctor think need . After release hospital , must remain Houston area monitor infection transplant-related side effect Day +100 . During time , return clinic 2 time week . At visit , blood ( 2 teaspoon ) draw routine test , check kidney liver function , check level tacrolimus ( drug part standard care outside study ) blood . Once week , blood also test cytomegalovirus ( CMV ) infection . At time engraftment , Days 30 , 60 , 100 day transplant , blood ( 2 teaspoon ) draw chimerism testing , look see much blood cell tissue mixed donor recipient . This test show well transplant `` take . '' About 2 month transplant : - Blood ( 2 teaspoon ) draw chimerism test . - You bone marrow biopsy check status disease . To collect bone marrow biopsy , area hip site numb anesthetic , small amount bone marrow bone withdrawn large needle . Blood ( 7 tablespoon time ) drawn check function NK cell : - Before NK cell infusion - On Days +1 , +7 , +14 , +28 , +45 , +60 , +100 - At Months 6 , 9 , 12 NK cell infusion Follow-Up Visits : You routine test part transplant follow-up care , often doctor think need . Length Study : You study 2 year follow yearly part regular care . You may take study early disease get bad , graft failure , unable receive NK cell infusion , intolerable side effect , unable follow study direction , doctor think best interest , study stop , choose leave study early . You talk study doctor want leave study early . The doctor tell effect stop treatment . You doctor talk follow-up care test would help . If take study early , still may need return routine post-transplant follow-up visit , doctor decides need . If leave study , test result information remove study record . This investigational study . Busulfan , fludarabine , clofarabine , ATG , rituximab , cyclophosphamide , mesna , melphalan FDA approve commercially available treatment blood cancer and/or use stem cell transplant . The way researcher process NK cell way infused FDA approve . These process currently use research purpose . Up 100 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<criteria>1 . Patients must one follow hematologic malignancy : Acute Myelogenous Leukemia ( AML ) , induction failure , highrisk relapse first remission ( intermediaterisk highrisk cytogenetics include complex karyotype , abn ( 3q ) , 5/5q , 7/7q , abn ( 12p ) , abn ( 17p ) , MLL gene rearrangement ( 6 ; 9 ) 47 , flt3 mutation positive and/or evidence minimal residual disease flow cytometry ) , secondary leukemia prior chemotherapy and/or arise MDS , disease beyond first remission . 2 . Myelodysplastic Syndrome ( MDS ) : Primary therapy relate , include patient consider transplant . These include follow category : 1 ) revise IPSS intermediate high risk group , 2 ) MDA transfusion dependency , 3 ) failure respond progression disease hypomethylating agent , 4 ) refractory anemia excess blast , 5 ) transformation acute leukemia , 6 ) chronic myelomonocytic leukemia , 7 ) atypical MDS/myeloproliferative syndrome , 8 ) complex karyotype , abn ( 3g ) , 5/5g , 7/7g , abn ( 12p ) , abn ( 17p ) . 3 . Acute Lymphoblastic Leukemia ( ALL ) : Induction failure , primary refractory treatment ( achieve complete remission first course therapy ) beyond first remission include second great remission active disease . Patients first remission eligible consider high risk , define follow detected time : translocation 9 ; 22 4 ; 11 , hypodiploidy , complex karyotype , secondary leukemia develop cytotoxic drug exposure , and/or evidence minimal residual disease4 acute biphenotypic leukemia , double hit nonHodgkin 's lymphoma . 4 . NonHodgkin 's Lymphoma ( NHL ) second third complete remission , relapse ( include relapse post autologous hematopoietic stem cell transplant ) . Relapsed double hit lymphoma . Patients option treatment know curative eligible . 5 . Small Lymphocytic Lymphoma ( SLL ) , Chronic lymphocytic Leukemia ( CLL ) progressive disease follow minimum two line standard therapy . 6 . CML second chronic phase accelerate phase . 7 . Hodgkin 's Disease ( HD ) : Induction failure , first complete remission , relapse ( include relapse post autologous hematopoietic stem cell transplant ) , active disease . 8 . Multiple Myeloma : stage II III , symptomatic , secretory Multiple Myeloma require treatment . 9 . A person ( haploidentical family member ) unit cord blood must identify source backup cell source case engraftment failure . 10 . Patient Age Criteria : Age &gt; /= 18 &lt; /= 55 year ( Myeloablative Regimen 1 . Patients &gt; /= 55 &lt; /= 65 year Performance Status 0 1 comorbidities may receive myeloablative regimen 1 discretion investigator ( ) . Age &gt; /= 18 &lt; /= 80 year ( Nonmyeloablative Regimen 2 ) . Age &gt; /= 18 &lt; /= 80 year old opinion investigator ( ) would preclude myeloablative therapy may receive reduce intensity regimen 3 . 11 . Performance score least 60 % Karnofsky 12 . Adequate major organ system function demonstrate : Left ventricular ejection fraction least 40 % ( Myeloablative Regimen 1 , Reduced Intensity Regimen 3 ) . Left ventricular ejection fraction least 30 % ( Nonmyeloablative Regimen 2 ) . 13 . Pulmonary function test ( PFT ) demonstrate adjust diffusion capacity least 50 % predict value hemoglobin concentration ( Myeloablative Regimen 1 , Reduced Intensity Regimen 3 ) . 14 . Serum creatinine within normal range , serum creatinine outside normal range , renal function ( measure estimate creatinine clearance GFR ) &gt; 40mL/min/1.73 m2 . 15 . SGPT/bilirubin &lt; 2.0 x normal ( Myeloablative Regimen 1 ) , Reduced Intensity Regimen 3 . SGPT/bilirubin &lt; 4.0 x normal ( Nonmyeloablative Regimen 2 ) . 16 . Negative Beta HCG test woman child bear potential define postmenopausal 12 month . 17 . Patients option treatment know curative eligible . 1 . HIV positive . HIV result determine nucleic acid test 2 . Uncontrolled serious medical condition persistent septicemia despite adequate antibiotic therapy , decompensated congestive heart failure despite cardiac medication pulmonary insufficiency require intubation ( exclude primary disease CB transplantation propose ) , psychiatric condition would limit informed consent . 3 . Active CNS disease patient history CNS malignancy . 4 . Availability appropriate , willing , HLAmatched relate stem cell donor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Acute Myelogenous Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Myelodysplastic syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>Multiple myeloma</keyword>
	<keyword>MM</keyword>
	<keyword>Umbilical cord blood transplant</keyword>
	<keyword>UCB</keyword>
	<keyword>Natural killer cell</keyword>
	<keyword>NK</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Busulfex</keyword>
	<keyword>Myleran</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Fludarabine Phosphate</keyword>
	<keyword>Fludara</keyword>
	<keyword>Clofarabine</keyword>
	<keyword>Clofarex</keyword>
	<keyword>Clolar</keyword>
	<keyword>Rabbit ATB</keyword>
	<keyword>ATG ( Rabbit )</keyword>
	<keyword>Rabbit Antithymocyte Globulin</keyword>
	<keyword>Rabbit Antilymphocyte Globulin</keyword>
	<keyword>rATG Thymoglobulin</keyword>
	<keyword>Total Body Irradiation</keyword>
	<keyword>TBI</keyword>
	<keyword>Radiation therapy</keyword>
	<keyword>XRT</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Neosar</keyword>
	<keyword>Melphalan</keyword>
	<keyword>Alkeran</keyword>
</DOC>